{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:48:02Z","timestamp":1790732882675,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI142415"],"award-info":[{"award-number":["R21AI142415"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R21GM136002"],"award-info":[{"award-number":["1R21GM136002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01EB023812"],"award-info":[{"award-number":["5R01EB023812"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01HL145031"],"award-info":[{"award-number":["5R01HL145031"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK114506"],"award-info":[{"award-number":["R01DK114506"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011781","name":"Shriners Hospitals for Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.biopha.2021.112377","type":"journal-article","created":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T22:46:26Z","timestamp":1641077186000},"page":"112377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver"],"prefix":"10.1016","volume":"146","author":[{"given":"Camilo","family":"Rey-Bedon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peony","family":"Banik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslihan","family":"Gokaltun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin.L.","family":"Yarmush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Korkut","family":"Uygun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Berk","family":"Usta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.biopha.2021.112377_bib1","doi-asserted-by":"crossref","first-page":"8364","DOI":"10.3748\/wjg.v20.i26.8364","article-title":"Experimental models of non-alcoholic fatty liver disease in rats","volume":"20","author":"Kucera","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2021.112377_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2018.06.029","article-title":"Human-based systems: mechanistic NASH modelling just around the corner?","volume":"134","author":"Boeckmans","year":"2018","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.biopha.2021.112377_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/HCO.0b013e328354829c","article-title":"Non-alcoholic fatty liver disease and vascular risk","volume":"27","author":"Bhatia","year":"2012","journal-title":"Curr. Opin. Cardiol."},{"issue":"16","key":"10.1016\/j.biopha.2021.112377_bib4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112377_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep4.1054","article-title":"Non-alcoholic steatofibrosis independently predicts mortality in non-alcoholic fatty liver disease","volume":"1","author":"Younossi","year":"2017","journal-title":"Hepatol. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2021.112377_bib6","first-page":"212","article-title":"Role of non-alcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity","volume":"3","author":"Massart","year":"2017","journal-title":"J. Clin. Transl. Res."},{"issue":"3","key":"10.1016\/j.biopha.2021.112377_bib7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/03602532.2011.577781","article-title":"Drug metabolism alterations in non-alcoholic fatty liver disease","volume":"43","author":"Merrell","year":"2011","journal-title":"Drug Metab. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2021.112377_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3748\/wjg.v23.i2.204","article-title":"Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease","volume":"23","author":"Kostrzewski","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.biopha.2021.112377_bib9","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of non-alcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.biopha.2021.112377_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2021.112377_bib11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","article-title":"Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation","volume":"392","author":"Zanger","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.biopha.2021.112377_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/PL00000897","article-title":"Cytochromes P450 and metabolism of xenobiotics","volume":"58","author":"Anzenbacher","year":"2001","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.biopha.2021.112377_bib13","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1124\/dmd.106.009670","article-title":"Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts","volume":"34","author":"Donato","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"19","key":"10.1016\/j.biopha.2021.112377_bib14","doi-asserted-by":"crossref","first-page":"28612","DOI":"10.18632\/oncotarget.8704","article-title":"Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.biopha.2021.112377_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.21840","article-title":"In vivo cytochrome P450 activity alterations in diabetic non-alcoholic steatohepatitis mice","volume":"31","author":"Li","year":"2017","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112377_bib16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jhep.2012.05.019","article-title":"Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis","volume":"57","author":"Abdelmegeed","year":"2012","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.biopha.2021.112377_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clinre.2011.04.015","article-title":"Increased expression of cytochrome P450 2E1 in non-alcoholic fatty liver disease: mechanisms and pathophysiological role","volume":"35","author":"Aubert","year":"2011","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112377_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd753","article-title":"PXR, CAR and drug metabolism","volume":"1","author":"Willson","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.biopha.2021.112377_bib19","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.tiv.2007.05.014","article-title":"Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells","volume":"21","author":"Westerink","year":"2007","journal-title":"Toxicol. Vitr."},{"issue":"28","key":"10.1016\/j.biopha.2021.112377_bib20","doi-asserted-by":"crossref","first-page":"29295","DOI":"10.1074\/jbc.M400580200","article-title":"Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by Phenytoin","volume":"279","author":"Wang","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2021.112377_bib21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0026-895X(25)13403-2","article-title":"Nuclear uptake of the Ah (dioxin) receptor in response to Omeprazole: transcriptional activation of the human CYP1A1 gene","volume":"43","author":"Quattrochi","year":"1993","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2021.112377_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229106","article-title":"A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction","volume":"15","author":"Bulutoglu","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2021.112377_bib23","doi-asserted-by":"crossref","first-page":"15848","DOI":"10.1038\/s41598-019-52174-w","article-title":"Rapid maturation of the hepatic cell line Huh7 via CDK inhibition for PXR dependent CYP450 metabolism and induction","volume":"9","author":"Bulutoglu","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2021.112377_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cotox.2019.03.001","article-title":"Human in vitro models of non-alcoholic fatty liver disease","volume":"16","author":"M\u00fcller","year":"2019","journal-title":"Curr. Opin. Toxicol."},{"issue":"20","key":"10.1016\/j.biopha.2021.112377_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90954","article-title":"Development of an in vitro human liver system for interrogating non-alcoholic steatohepatitis","volume":"1","author":"Feaver","year":"2016","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.biopha.2021.112377_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/096032719901800206","article-title":"Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by Omeprazole","volume":"18","author":"Shih","year":"1999","journal-title":"Hum. Exp. Toxicol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112377_bib27","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.biopha.2021.112377_bib28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/MCG.0000000000000116","article-title":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"48","author":"Labrecque","year":"2014","journal-title":"J. Clin. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112377_bib29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jhep.2018.06.023","article-title":"Urea cycle dysregulation in non-alcoholic fatty liver disease","volume":"69","author":"De Chiara","year":"2018","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2021.112377_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1096\/fasebj.3.2.2914628","article-title":"function and extracellular matrix geometry: long-term culture in a sandwich configuration","volume":"3","author":"Dunn","year":"1989","journal-title":"FASEB"},{"issue":"9","key":"10.1016\/j.biopha.2021.112377_bib31","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1111\/ajt.15330","article-title":"The impact of postreperfusion syndrome during liver transplantation using livers with significant macrosteatosis","volume":"19","author":"Croome","year":"2019","journal-title":"Am. J. Transpl."},{"issue":"6696","key":"10.1016\/j.biopha.2021.112377_bib32","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/29788","article-title":"Decreased lesion formation in CCR2-\/- mice reveals a role for chemokines in the initiation of atherosclerosis","volume":"394","author":"Boring","year":"1998","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2021.112377_bib33","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1007\/s00125-012-2710-2","article-title":"Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M2 macrophages and ameliorates insulin resistance and fatty liver in lipoatrophic diabetic A-ZIP transgenic mice","volume":"55","author":"Nio","year":"2012","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.biopha.2021.112377_bib34","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jhep.2014.07.006","article-title":"CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis","volume":"61","author":"Zhang","year":"2014","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112377_bib35","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/hep.28252","article-title":"Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes","volume":"63","author":"Ibrahim","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.biopha.2021.112377_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1530\/JOE-15-0409","article-title":"Metformin improves hepatic IRS2\/PI3K\/Akt signaling in insulin-resistant rats of NASH and cirrhosis","volume":"229","author":"Xu","year":"2016","journal-title":"J. Endocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112377_bib37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/MEG.0b013e3283229b40","article-title":"Could inflammatory markers help diagnose non-alcoholic steatohepatitis?","volume":"21","author":"Tarantino","year":"2009","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2021.112377_bib38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hep.28456","article-title":"Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis","volume":"64","author":"Tilg","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2021.112377_bib39","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2011.04.007","article-title":"IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation","volume":"55","author":"Tilg","year":"2011","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2021.112377_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1021\/cb900006h","article-title":"A novel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450(BM3)","volume":"4","author":"Dietrich","year":"2009","journal-title":"ACS Chem. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2021.112377_bib41","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2021.112377_bib42","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am. Fam. Physician"},{"issue":"7","key":"10.1016\/j.biopha.2021.112377_bib43","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1124\/dmd.30.7.795","article-title":"CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes","volume":"30","author":"Luo","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.biopha.2021.112377_bib44","first-page":"595","article-title":"Cytochrome P450 1A1 (CYP1A1) catalyzes lipid peroxidation of oleic acid-induced HepG2 cells","volume":"83","author":"Huang","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2021.112377_bib45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.fct.2018.01.029","article-title":"Cytochrome P450 1A1 (CYP1A1) protects against non-alcoholic fatty liver disease caused by Western diet containing benzo[a]pyrene in mice","volume":"113","author":"Uno","year":"2018","journal-title":"Food Chem. Toxicol."},{"issue":"5","key":"10.1016\/j.biopha.2021.112377_bib46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug-drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2021.112377_bib47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.pharmtox.45.120403.095821","article-title":"Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics","volume":"45","author":"Rettie","year":"2005","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"10.1016\/j.biopha.2021.112377_bib48","unstructured":"G. Alghaith, Expressionn and activity of CYP2C8 and 2C9 in diabetes mellitus and nonalcoholic fatty liver disease Open Access Master'S. Theses Paper, 1400, 2018."},{"issue":"3","key":"10.1016\/j.biopha.2021.112377_bib49","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.yexmp.2015.11.008","article-title":"Induction of CYP2E1 in non-alcoholic fatty liver diseases","volume":"99","author":"Aljomah","year":"2015","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.biopha.2021.112377_bib50","doi-asserted-by":"crossref","first-page":"10775","DOI":"10.1038\/srep10775","article-title":"Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system","volume":"5","author":"Koussounadis","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2021.112377_bib51","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/1471-2164-10-365","article-title":"Correlations between RNA and protein expression profiles in 23 human cell lines","volume":"10","author":"Gry","year":"2009","journal-title":"BMC Genom."},{"issue":"3","key":"10.1016\/j.biopha.2021.112377_bib52","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","article-title":"On the dependency of cellular protein levels on mRNA abundance","volume":"165","author":"Liu","year":"2016","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.biopha.2021.112377_bib53","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999 to 2012","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2021.112377_bib54","unstructured":"National Center for Health Statistics. Prescription drug use in the past 30 days, by sex, race and Hispanic origin, and age: United States, selected years 1988\u20131994 through 2013\u20132016, 2018, 2018. \u3008https:\/\/www.cdc.gov\/nchs\/data\/hus\/2018\/038.pdf\u3009."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221011616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:59:30Z","timestamp":1779965970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221011616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":54,"alternative-id":["S0753332221011616"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112377","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.112377","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112377"}}